|
|
 |
 |
 |
| Aerovance,
Inc. |
|
 NGN
Capital participated in the initial $32 million Series B
and subsequent $60 million Series C financings of Aerovance,
Inc., a spin-out from Bayer Pharmaceuticals.
Aerovance is a biotherapeutics company focused on developing
and commercializing products for novel targets in respiratory
and inflammatory diseases. The Company has four Phase IIa
clinical programs in development directed towards asthma,
chronic obstructive pulmonary disease (COPD), eczema, and
cystic fibrosis. Aerovance targets products with substantial
market potential, which fill significant unmet medical needs.
Dr. Georg Nebgen, Managing General Partner of NGN Capital,
formerly held an observer seat on the board of directors.
Aerovance is located in Berkley, CA
Latest
News
www.aerovance.com
|
| Artes
Medical, Inc. (NASDAQ:ARTE) |
|
 NGN
capital participated in a $50.7 million Series E financing
for Artes Medical, Inc., which has launched an injectable
dermal filler for use in aesthetic plastic surgery and dermatology.
Artes went public in December, 2006.
Artes’ filler, ArteFill®, is targeted at the
treatment of wrinkles known as naso-labial folds or smile
lines. ArteFill consists of a combination of ultra-purified
bovine collagen and acrylic microspheres. ArteFill’s
differentiation is that it provides significantly longer
lasting benefit than other fillers currently being marketed.
In addition, the company is exploring several other applications
of the technology.
John R. Costantino, Managing General Partner of NGN Capital,
holds a seat on the board of directors.
Artes Medical, Inc. is located in San Diego, CA.
Latest
News
www.artesmedical.com
|
| Artisan
Pharma, Inc. |
|
 NGN
Capital led a $39 million Series A financing of Artisan
Pharma, Inc., a spin-out from Asahi Kasei Pharma Corporation
(AKP) of Japan.
Artisan Pharma, is focused on developing and commercializing
products in critical care and hospital-based markets. As
part of the financing, AKP has licensed a late-stage clinical
development biologic, ART-123, to Artisan. ART-123 is a
novel, recombinant, soluble, human thrombomodulin being
developed for the treatment of DIC (disseminated intravascular
coagulation) in sepsis and DVT (deep vein thrombosis). Phase
III studies have been completed for ART-123 and the JNDA
was submitted in Japan. Phase 2b studies of ART-123 for
DIC in sepsis are planned in the US.
Dr. Georg Nebgen and John R. Costantino, both Managing
General Partners of NGN Capital, hold seats on the board
of directors.
Artisan is located in Waltham, MA.
Latest
News
www.artisanpharma.net
|
| |
| BeneChill,
Inc. |
NGN Capital led a $7 million Series B financing of
BeneChill, Inc., an innovative medical device company
that is developing a device to deliver therapeutic hypothermia
to the brain.
BeneChill is developing non-invasive cooling technology
for treatment following ischemic stroke, cardiac arrest
or traumatic brain injury. Reducing brain temperature
is believed by medical experts to reduce damage to the
brain following such events. Relative to other cooling
technologies, BeneChill’s cooling technology can
be deployed earlier, cools more rapidly and is selective
to the brain.
Noah J. Kroloff, Partner of NGN Capital, holds a seat
on the BeneChill board of directors and Kenneth S. Abramowitz,
Managing General Partner of NGN Capital, holds an observer
seat.
BeneChill, Inc. is located in San Diego, CA.
Latest
News
www.benechill.com
|
| BioArray
Solutions Ltd. |
|  NGN
Capital led the $20 million Series C/D and the $25 million
Series E financings of BioArray Solutions Ltd.
BioArray is a molecular diagnostics company that has developed
a novel chip-based assay system to serve the needs of medium
and larger clinical laboratories. The initial applications
are in the blood transfusion and organ transplant donor
matching areas. BioArray Solutions combines assay systems
that are extremely accurate in even the most complex biological
situations with low cost and scalability.
William J. Gedale, Managing General Partner of NGN Capital,
holds a seat on the board of directors.
BioArray Solutions, Ltd. is located in Warren, NJ
Latest
News
www.bioarrays.com
|
| EKOS
Corp. |
|
 NGN
Capital led the second tranche of an $18 million Series
B financing.
EKOS Corporation has developed an intravascular catheter
platform using low energy ultrasound to enhance drug delivery
through EKOS infusion catheters. Initial applications are
in stroke and peripheral arterial occlusion (PAO) disease.
The company currently sells the EKOS catheter for use in
PAO and is in NIH sponsored clinical trials for embolic
stroke. Both the PAO market as well as the market for embolic
stroke represent large markets with significant unmet clinical
needs.
Ken Abramowitz, Managing General Partner of NGN Capital,
holds a seat on the board of directors.
EKOS is located in Bothell, WA
Latest
News
www.ekoscorp.com
|
| Javelin
Pharmaceuticals, Inc. (AMEX:JAV) |
|  NGN
Capital led a $32 million PIPE financing of Javelin Pharmaceuticals,
Inc.
Javelin is a specialty pharmaceutical company focusing on
the growing pain management market with three late stage
products in Phase III clinical development or in the regulatory
filing process. One of these products, Dyloject®, the
first bolus injectable diclofenac formulation, has been
approved for sale in the UK. Javelin has submitted Dyloject
for European Marketing Authorization Application (MAA).
Dyloject™ is posed to fill the void created by the
stumbling of COX-2 inhibitors in both EU and US markets
with a non-selective COX inhibitor. Combined with its Phase
II / III PMI-150 (intranasal ketamine) and Rylomine™
(intranasal morphine) products, Javelin is building an exciting
franchise in the moderate-to-severe and breakthrough pain
markets.
Dr. Georg Nebgen, Managing General Partner of NGN Capital,
holds a seat on the board of directors.
Javelin Pharmaceuticals is located in New York, NY.
Latest
News
www.javelinpharmaceuticals.com
|
| Jerini
AG (FRANKFURT: JI4) |
|
 NGN
Capital led the € 15.5 million Series B second closing
following the € 31 million intial round, for a total
€ 46.5 million Series B financing of Jerini, AG. Jerini
went public in November, 2005.
Jerini is a late stage biopharmaceutical company that has
completed Phase III clinical trials of Icatibant for the
treatment of Hereditary Angioedema (HAE). HAE is a debilitating,
potentially life-threatening disease caused by attacks of
swelling in the face, throat, abdomen and other parts of
the body. Jerini is focused on the discovery, development
and commercialization of peptide derived (peptidomimetic)
and small molecule therapeutics and has a deep pipeline
of preclinical products from its Peptide-to-Drugs platform.
Jerini is located in Berlin, Germany.
Latest
News
www.jerini.de
|
| KIKA
Medical, Inc. |
|  NGN
Capital led a € 7.5 million Series B investment in
KIKA Medical, Inc.
KIKA offers the first fully integrated web-based clinical
trial data management platform utilizing novel software
architecture and advanced professional services. Kika’s
Eventa™ Suite allows the customer to seamlessly build,
operate, track, analyze and audit clinical studies with
novel data handling and evaluation capabilities. The system
has powerful monitoring & process controls and is fully
FDA 21 CFR Part 11 compliant. It generates substantial cost
and time savings for the customer. The company has a strong
customer base and worldwide clinical trial knowledge, having
supported more than 100 studies across 60 countries.
William J. Gedale and Dr. Georg Nebgen, Managing General
Partners of NGN Capital, both hold seats on the board of
directors.
KIKA is located in Boston, MA.
Latest
News
www.kikamedical.com
|
| Micromet
Inc. (NASDAQ:MITI) |
|  NGN
Capital invested $8 million in a PIPE transaction in Micromet
Inc.
Micromet, Inc. is a biopharmaceutical
company focusing on the development of novel, proprietary
antibody-based products for cancer, inflammatory and autoimmune
diseases. Two product candidates are currently in clinical
trials. Adecatumumab (MT 210), a recombinant human monoclonal
antibody, is being evaluated in Phase II clinical trials
for the treatment of patients with breast cancer and prostate
cancer. MT103 (MEDI-538), a BiTE® product candidate,
is being studied in a Phase I clinical trial for the treatment
of patients with non-Hodgkin’s lymphoma. Micromet
has established a drug development platform based on its
BiTE® technology, a unique, antibody-based format that
leverages the cytotoxic potential of T-cells, the most powerful
“killer cells” of the human immune system. Micromet
has established collaborations with MedImmune, Serono and
Enzon.
Dr. Peter Johann, Managing General Partner of NGN Capital,
holds a seat on the board of directors.
Micromet is located in Bethesda, MD
Latest
News
www.micromet.de
|
| MultiPlan |
|
 NGN
Capital, in its first buyout, joined with The Carlyle Group
to acquire MultiPlan, the largest independent preferred
provider organization (PPO) in the U.S.
MultiPlan is the nation’s oldest and largest independent
PPO network offering nationwide access to more than 4,200
hospitals, 100,000 ancillary care facilities and 550,000
physicians and specialists. The company’s 2,000 clients
include large and mid-sized insurers, third-party administrators,
self-funded plans, HMOs and other entities that pay claims
on behalf of health plans.
PPOs, which are the most common type of health plan in the
U.S. today, offer a provider network and range of value-added
services to help employers and other health plan sponsors
manage the cost of medical claims. MultiPlan offers a full
range of medical cost management solutions to a blue-ribbon
list of clients, including the national PPO network, specialty
networks, negotiation services and electronic claim routing
technology.
Kenneth S. Abramowitz, Managing General Partner of NGN
Capital, holds a seat on the board of directors.
MultPlan is located in New York, NY.
Latest
News
www.multiplan.com
|
| NanIRx |
| 
NGN Capital led a $6.75M Series A financing of NanIRx Therapeutics,
Inc.
NanIRx Therapeutics is developing a novel class of therapeutics
based on the use of Tat (transactivator protein from HIV)
and Tat derivatives, as well as Tat-derived conjugates.
The derivatives act through a novel mechanism of action
targeting chronic infectious diseases, cancer, autoimmune
diseases and organ transplant rejection. The therapeutics
fall broadly into two categories either stimulating or suppressing
the innate immune system in a disease-targeted manner.
Dr. Peter Johann and William Gedale, Managing General Partners
of NGN Capital, serve as chairman and member of the board
of directors, respectively.
NanIRx Therapeutics is located in New York, NY
www.nanirx-pharma.com
|
| Nitec
Pharma AG |
|
 NGN
Capital led a Series B financing of CHF 32 million (approx.
US$ 26 million) of Nitec Pharma AG.
Nitec Pharma is a specialty pharmaceutical company focused
on the development and commercialization of optimized medicines
for the treatment of chronic inflammatory diseases. Nitec
is developing Lodotra™, a night time release formulation
of prednisone, to address morning symptoms such as morning
stiffness in rheumatoid arthritis. Lodotra has completed
Phase III trials and will also be developed to treat other
indications such as Polymyalgia Rheumatica (PMR), asthma
and other inflammatory diseases. Nitec was originally founded
in 2004 in a spin-out from Merck KGaA. Lodotra was originally
developed at Merck in cooperation with SkyePharma using
SkyePharma’s GEOLOCK™ technology.
Dr. Peter Johann, Managing General Partner of NGN Capital,
holds a seat on the board of directors and Dr. Ivica Cerina
holds an observer seat.
Nitec is located in Basel, Switzerland.
Latest
News
www.nitecpharma.com
|
| OptiScan
Biomedical Corp. |
|
 NGN
Capital led a $36 million Series B financing of OptiScan
Biomedical Corporation, an innovative diagnostic equipment
company.
OptiScan is focused on further developing and commercializing
its system for continuously measuring blood glucose and
other analytes in order to support tight glycemic control.
Tight glycemic control has been shown in various clinical
studies to improve outcomes for hospital patients in intensive
care.
Kenneth S. Abramowitz, Managing General Partner of NGN
Capital, holds a seat on the board of directors.
OptiScan is based in Hayward, CA.
www.farir.com
|
| Power
Medical Interventions, Inc. (NASDAQ: PMII) |
NGN Capital co-led a $35 million Series B financing of
Power Medical Interventions, Inc. (PMI). PMI is focused
on developing and commercializing novel high technology
surgical stapling closure devices for operating room use.
Power Medical went public in October, 2007.
PMI holds more than two dozen U.S. patents covering the
pioneering use of computer-assisted, electrical powered
placement of surgical staples for wound closure. This
advanced minimally invasive staple technology significantly
improves the accuracy, speed and safety of gastrointestinal
and pulmonary surgical procedures, allowing surgeons to
more confidently close bowel and lung tissue. In the future,
these instruments will increasingly facilitate surgery
that would not be readily feasible with traditional, manual
stapling techniques, such as deep bowel surgery and per-oral
anastomoses for weight loss surgery. Additionally, PMI
possesses a rich pipeline of follow-on products. PMI launched
the product line in 2002 and is actively selling to surgeons.
Kenneth S. Abramowitz, Managing General Partner of NGN
Capital, holds a seat on the board of directors.
Power Medical Interventions, Inc. is located in Langhorne,
PA.
Latest
News
www.pmi2.com
|
| Santhera
Pharmaceuticals AG (SWX:SANN) |
NGN Capital led the Series B financing (€ 43 million)
and pre-IPO rounds of Santhera Pharmaceuticals AG. Santhera
went public in November, 2006.
Santhera is a late stage specialty pharmaceutical company
with a neuromuscular disease focus. Santhera is in Phase
III clinical development in the US and in the Marketing
Authorization Application process in Europe for idebenone
for the treatment of cardiomyopathy related to Friedreich’s
Ataxia. Additional indications for idebenone are in
Phase II, including Duchenne Muscular Dystrophy (DMD)
and Leber's Hereditary Optic Neuropathy (LHON).
Santhera has valuable pharma/biotech marketing/development
partnerships in Dyskinesia in Parkinson’s Disease,
Congenital Muscular Dystrophy (CMD), and in type II
diabetes.
Dr. Georg Nebgen, Managing General Partner of NGN Capital,
holds a seat on the board of directors.
Santhera Pharmaceuticals is located in Liestal, Switzerland.
Latest
News
www.santhera.com
|
| Sightline
Technologies Ltd. |
NGN Capital led a $10 million Series D financing of
Sightline Technologies Ltd., an innovative medical device
company located in the Advanced Technology Center in
Haifa, Israel. Sightline is focused on commercializing
and further developing the FDA-cleared ColonoSight®
system, a colonoscope with a disposable ColonoSleeve®
tube and sheath, which is used for diagnosing and treating
abnormalities in the large intestine.
The company’s advanced disposable technology potentially
improves safety and speed relative to traditional colonoscopy
systems, while the protective sheath places a disposable
barrier between the patient, the scope, and the physician.
Kenneth S. Abramowitz and John R. Costantino, both NGN
Capital Managing General Partners, formerly held a board
seat and an observer seat, respectively.
In March, 2006, Sightline was acquired by Stryker Corporation.
(Please see press release for
additional information.)
Sightline Technologies is located in Haifa, Israel.
Latest
News
www.sightline.co.il
|
| Small
Bone Innovations, Inc. |
NGN Capital and 3i co-led a $42 million Series B financing
of Small Bone Innovations, Inc. (SBI).
SBI was the first company to focus purely on arthritis
and trauma in small bones and joints in the upper and
lower extremities (shoulder to fingertip and mid-calf
to the toe) and is executing a roll-up strategy in those
market segments. The company has a deep pipeline of
implants, fixation and tissue technology products which
will enable it to take advantage of the strong growth
in this niche of the orthopedics market.
Kenneth S. Abramowitz and John R. Costantino, both
Managing General Partners at NGN Capital, serve as member
and observer of the board of directors, respectively.
SBI is headquartered in New York, NY.
Latest
News
www.totalsmallbone.com
|
| |
| Tigris
Pharmaceuticals, Inc. |
 NGN
Capital led a $16 million Series B financing round for Tigris
Pharmaceuticals, Inc.
Tigris has acquired the commercial rights to several therapeutic
products which address unmet medical needs in the treatment
of cancer and HPV virus induced precancerous tissues. Tigris’
lead compound, A-007, is a topical gel for the treatment of
cervical intra-epithelial neoplasia (CIN) resulting from the
human papilloma virus (HPV). A-007 represents a non-invasive
alternative to the current standard of care, loop electrosurgical
excision surgery (LEEP), and thus constitutes a significant
advance in women’s healthcare. If left untreated CIN
may progress to cervical cancer. A-007 complements the use
of prophylactic vaccines to reduce the incidence of cervical
cancer. Tigris has three additional innovative programs in
early clinical or advanced pre-clinical development targeting
solid tumors.
Dr. Georg Nebgen, Managing General Partner of NGN Capital,
holds a seat on the board of directors.
Tigris is located in Bonita Springs, FL.
Latest
News
www.tigrispharma.com
|
|
| |
|
Top
of Page
Print Version
|
|
|
